SCHEMBL5015733

SCHEMBL5015733

CCOC(Cc1cccc2c1ccn2Cc1nc(-c2ccccc2)oc1C)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 20/20 1.00
PPARA Q07869 19/20 1.00
PPARD Q03181 14/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5017281 0.94 PPARG (0.89) PPARGPPARAPPARD
SCHEMBL5015834 0.93 PPARG (0.86) PPARGPPARAPPARD
SCHEMBL5015810 0.92 PPARG (0.85) PPARGPPARAPPARD
SCHEMBL5015854 0.91 PPARG (0.91) PPARGPPARAPPARD
SCHEMBL5015882 0.91 PPARG (0.83) PPARGPPARAPPARD
SCHEMBL5015790 0.91 PPARG (0.83) PPARGPPARAPPARD
SCHEMBL5017991 0.91 PPARG (0.83) PPARGPPARAPPARD
SCHEMBL5015822 0.90 PPARG (0.82) PPARGPPARAPPARD
SCHEMBL5015749 0.90 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL5015858 0.89 PPARG (0.80) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567523-B1 INDOLYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-08-20 EP claimed
US-7098228-B2 e.g., 3-{1-[2-(3,5-Dimethoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-4-yl}-2-ethoxy-propionic acid ethyl ester; treating non-insulin dependent diabetes mellitus; PPAR receptor activation HOFFMANN-LA ROCHE INC. (US) 2006-08-29 US claimed
EP-1567523-A1 INDOLYL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP claimed
WO-2004048371-A1 INDOLYL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO claimed
US-20040106657-A1 Indolyl derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-06-03 US claimed
EP-1567523-B1 INDOLYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-08-20 EP disclosed
US-7098228-B2 e.g., 3-{1-[2-(3,5-Dimethoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-4-yl}-2-ethoxy-propionic acid ethyl ester; treating non-insulin dependent diabetes mellitus; PPAR receptor activation HOFFMANN-LA ROCHE INC. (US) 2006-08-29 US disclosed
EP-1567523-A1 INDOLYL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
WO-2004048371-A1 INDOLYL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed
US-20040106657-A1 Indolyl derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106657-A1 Indolyl derivatives GPR119, IRS1, INSR PPARG 354/4885PPARA 286/4885PPARD 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.